Federal Judge Transfers Case Challenging FDA’s Mifepristone Approval to Missouri Court

A federal judge in Texas, known for his conservative and religiously influenced rulings, has stepped down from a case seeking to challenge the FDA’s approval of the abortion drug mifepristone. Judge Matthew Kacsmaryk has transferred the case, originally filed in his Amarillo court, to a federal court in Missouri where it may be further debated.

The case, once called FDA v. Alliance for Hippocratic Medicine, was brought by anti-abortion groups claiming that the FDA exceeded its authority in approving mifepristone in 2000 and during subsequent administrations. However, last year, the U.S. Supreme Court unanimously ruled that these groups lacked standing to sue, meaning they failed to prove direct harm from the FDA’s decisions.

The court’s decision opened the door for intervention by states like Missouri, Idaho, and Kansas, which sought to continue the legal challenge. Kacsmaryk’s recent ruling moved the case to the Eastern District of Missouri, a jurisdiction with a predominantly conservative judiciary, including several Trump appointees, some with direct ties to the state attorney general’s office involved in the case.

The transfer aligns with federal law allowing cases to be moved to any district where they could have originally been filed. Critics argue that the current Missouri court’s composition was chosen deliberately, given its history of siding with conservative causes, including past rulings favoring anti-abortion efforts.

This move comes despite the FDA’s repeated affirmations of mifepristone’s safety, especially as medication abortions now account for over 60% of all abortions in the U.S. in the post-Roe era. The ongoing legal battles reflect the broader political and ideological conflict surrounding reproductive rights in the country.